USE OF PERAMPANEL IN THE TREATMENT OF EPILEPSY: A REVIEW OF LITERATURE AND A CASE REPORT

Despite a considerable advance made in epileptology, resistant epilepsies account for approximately 30 % of all forms of epilepsy particularly in patients with focal seizures. The most common structural cause of resistant epilepsies in children is focal cortical dysplasias that are varieties of abnormal cortical development. The term “focal cortical dysplasia” was first mentioned by D. Taylor et al. in 1971 to denote local abnormalities of cortical development in our 10 described patients with resistant epilepsy. According to К. Watanabe et al. (1996), focal cortical dysplasias as a cause of epilepsy are detected in 3.0–4.3 % of patients with different forms of epilepsy. Among all abnormalities of cortical development in children who have undergone surgery for epilepsy, focal cortical dysplasias amount to 75 %, as shown by the data obtained by I. Blümcke et al. (2009).

In resistant epilepsy, there is a hope for successful neurosurgical treatment and synthesis of novel antiepileptic drugs (AEDs). The authors present a review dedicated to the novel AED perampanel and consider its mechanism of action, pharmacokinetic features, indications for use, and the results of clinical trials and postmarket researches of the efficacy, tolerability, and safety of the drug, including its recent investigations. The paper describes a clinical case of successfully using perampanel in a patient with therapy-resistant epilepsy caused by focal cortical dysplasia. Based on the data available in the literature and the authors’ own cases, it тay be concluded that perampanel is a promising drug in treating epilepsy (even in epilepsies resistant to many other AEDs) with favorable indicators of tolerability. 

1. Власов П.Н. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):5. [Vlasov P.N. Clinical case of application of Fycompa. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):5. (In Russ.)].

2. Жидкова И.А. Управление нежелательными явлениями, возникающими на фоне приема перампанела. Эпилепсия и пароксизмальные состояния 2014; (спецвыпуск):13–4. [Zhidkova I.A. Management of undesirable adverse effects that arise on the background of perampanel intake. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):13–4. (In Russ.)].

3. Мухин К.Ю., Пылаева О.А. Применение перампанела (Файкомпы) в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Святителя Луки). Русский журнал детской неврологии 2014;9(4):14–9. [Mukhin K.Yu., Pylaeva O.A. Perampanel (Fycompa) for treatment of epilepsy (experience of the Svt. Luka’s institute of child neurology and epilepsy). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;9(4):14–9. (In Russ.)]. DOI: 10.17650/2073-8803-2014-9-4-14-19.

4. Мухин К.Ю., Пылаева О.А., Миронов М.Б. Применение перампанела у ребенка с резистентной эпилепсией при синдроме Ангельмана. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):15. [Mukhin K.Yu., Pylaeva O.A., Mironov M.B. Perampanel for children with resistant epilepsy of the Angelman syndrome. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):15. (In Russ.)].

5. Перунова Н.Ю. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):9. [Perunova N.Yu. Clinical case of application of Fycompa. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):9. (In Russ.)]

6. Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата перампанел (Файкомпа) в лечении эпилепсии (обзор зарубежной литературы). Русский журнал детской неврологии 2014;9(3): 36–42. [Pylaeva O.A., Mukhin K.Yu. Use of the new antiepileptic drug perampanel (Fycompa) in the treatment of epilepsy: a review of foreign literature. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;9(3):36–42. (In Russ.)] DOI: 10.17650/2073-8803-2014-9-3-36-42.

7. Besag F.M., Patsalos P.N. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatr Dis Treat 2016;12:1215–20. DOI: 10.2147/NDT.S83842.

8. Blümcke I., Vinters H.V., Armstrong D. et al. Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord 2009;11(3):181–93. DOI: 10.1684/epd.2009.0261.

9. Franco V., Crema F., Iudice A. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70(1):35–40. DOI: 10.1016/j. phrs.2012.12.006.

10. French J.A., Krauss G.L., Biton V. et al. Adjunctive perampanel for refractory partialonset seizures: randomized phase III study 304. Neurology 2012;79(6):589–96. DOI: 10.1212/ WNL.0b013e3182635735.

11. French J.A., Krauss G.L., Steinhoff B.J. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54(1):117–25. DOI: 10.1111/j.1528-1167.2012.03638.x.

12. Guerrini R., Parrini E. Epilepsy and malformations of the cerebral cortex. In: Epileptic syndromes in infancy, childhood and adolescence. 5th ed. with video. Ed. by M. Bureau, P. Genton, C. Dravet et al. Paris: John Libbey Eurotext, 2012. Pp. 607–29.

13. Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014;9(4):449–58. DOI: 10.1517/17460441.2014.891580.

14. Hintz M., Nawratil S., Schulze-Bonhage A. Perampanel as a therapy option in patients with epilepsy. Nervenarzt 2016. [Epub ahead of print]. DOI: 10.1007/s00115-016-0131-z.

15. Kerling F., Kasper B.S. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):25–9. DOI: 10.1111/ane.12101.

16. Ko D., Ramsay R.E. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;(197):36–43. DOI: 10.1111/ane.12103.

17. Krauss G.L., Perucca E., Ben-Menachem E. et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia 2014;55(7):1058–68. doi: 10.1111/epi.12643.

18. Krauss G.L., Perucca E., Ben-Menachem E. et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54(1):126– 34. DOI: 10.1111/j.1528-1167.2012.03648.x.

19. Krauss G.L. Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr 2013;13(6):269–72. DOI: 10.5698/1535-7597-13.6.269.

20. Krauss G.L., Serratosa J.M., Villanueva V. et al. Randomized phase III study 306: adjunctive perampanel for refractory partialonset seizures. Neurology 2012;78(18):1408– 15. DOI: 10.1212/WNL.0b013e318254473a.

21. Krauss G.L., Bar M., Biton V. et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125(1):8–15. DOI: 10.1111/j.1600-0404.2011.01588.x.

22. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8. DOI: 10.1053/seiz.2000.0442.

23. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406. DOI: 10.1586/14737175.6.3.397.

24. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013;52(11):927–66. DOI: 10.1007/s40262-013-0087-0.

25. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013;52(12):1045–61. DOI: 10.1007/s40262-013-0088-z.

26. Rektor I., Krauss G.L., Bar M. et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263–9. DOI: 10.1111/ane.12001.

27. Rheims S., Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat 2013;9:629–37. DOI: 10.2147/NDT.S30129.

28. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11(2):56–63. DOI: 10.5698/1535-7511-11.2.56.

29. Rohracher A., Brigo F., Höfler J. et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 2016;17(10):1403–11. DOI: 10.1080/14656566.2016.1195810.

30. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:13–5. DOI: 10.1111/epi.12504.

31. Satlin A., Kramer L.D., Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl 2013;(197):3–8. DOI: 10.1111/ane.12098.

32. Serratosa J.M., Villanueva V., Kerling F., Kasper B.S. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):30–5. DOI: 10.1111/ane.12102.

33. Shih J.J., Tatum W.O., Rudzinski L.A. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285–93. DOI: 10.2147/TCRM.S37317.

34. Singh K., Shah Y.D., Luciano D. et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav 2016;61:41–5. DOI: 10.1016/j.yebeh.2016.05.007.

35. Steinhoff B.J., Bacher M., Bast T. et al. First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia 2014;55 Suppl 1:16–8. DOI: 10.1111/epi.12492.

36. Steinhoff B.J., Ben-Menachem E., Ryvlin P. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54(8):1481–9. DOI: 10.1111/epi.12212.

37. Steinhoff B.J., Hamer H., Trinka E. et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 2014;108(5):986–8. DOI: 10.1016/j.eplepsyres.2014.03.015.

38. Steinhoff B.J. Efficacy of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:9–12. DOI: 10.1111/epi.12493.

39. Wang Z.R., Alexopoulos A., Jones S.E. et al. The pathology of magnetic-resonance-imagingnegative epilepsy. Mod Pathol 2013;26(8):1051–8. DOI: 10.1038/modpathol.2013.52.

40. Watanabe K., Negoro T., Aso K. et al. Childhood-onset epilepsy due to focal cortical dysplasia. In: Dysplasias of cerebral cortex and epilepsy. Ed. by R. Guerrini, F. Andermann, R. Canapicchi et al. Philadelphia: Lippincott – Raven Publishers, 1996. Pp. 227--34.

41. Zwart R., Sher E., Ping X. et al. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl4-isoxazolepropionic acid receptors for the treatment of epilepsy: studies in human epileptic brain, non-epileptic brain, and in rodent models. J Pharmacol Exp Ther 2014;351(1): 124–33. DOI: 10.1124/jpet.114.212779.